MLYS · Mineralys Therapeutics, Inc.
$20.55
-4.29% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-8.4
Dividend yield
0.0%
Beta
0.69
Avg volume
1M
Employees
0K
Daily Change %
-4.29%
5 Days Change
5.76%
10 Days Change
2.24%
30 Days Change
-20.16%
60 Days Change
-15.04%
Month to Day Change
-9.49%
Year to Day Change
-40.84%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MLYS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-12
Latest call per bank · past 12 months
UBS
Neutral$29.00
+41.1% vs priceBank of America
Buy$51.00
+148.2% vs priceWells Fargo
Overweight$55.00
+167.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | UBS | Initiates | Neutral | $0.00 → $29.00 |
| 2026-10-12 | HC Wainwright & Co. | Reiterates | Buy | $56.00 |
| 2026-04-27 | TD Cowen | Initiates | Buy | $0.00 |
| 2026-03-13 | Bank of America | Maintains | Buy | $46.00 → $51.00 |
| 2025-12-19 | Stifel | Maintains | Buy | $45.00 → $52.00 |
| 2025-11-12 | HC Wainwright & Co. | Maintains | Buy | $52.00 → $56.00 |
| 2025-11-11 | Wells Fargo | Maintains | Overweight | $50.00 → $55.00 |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy | $42.00 → $52.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 37 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 18.9% below the 50-day MA ($25.35).
- bearish: Price vs 200-day MA: Trading 24.8% below the 200-day MA ($27.31).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.01) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($20.30).
MLYS Price Chart
Loading chart for MLYS…
Fundamentals
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.